Biogen Idec concedes more ground to Icahn
This article was originally published in Scrip
Executive Summary
Biogen Idec has reached a settlement with activist investor Carl Icahn, placating his demands for greater representation on the biotech's board. Mr Icahn agreed to abandon his quest to wrest control of the company in return for one seat on Biogen Idec's board.